Specifically, EGFL8 predicted poor prognosis for patients with COAD and KIRC, whereas it predicted a survival advantage for patients with PAAD and THYM (P < 0.05) (Supplementary Table 2). Here, EGFL8 is linked to pancreatic adenocarcinoma.